Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
empagliflozin + losartan + finerenone
- Development stage
- Preclinical
- Lead developer
- UT Southwestern Medical Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
empagliflozin + losartan + finerenone is an investigational fixed-dose combination (polypill) being evaluated by the University of Texas Southwestern Medical Center for the prevention of diabetic cardiomyopathy. This therapeutic strategy, studied in the PolyPreventHF trial, combines three classes of drugs known to provide cardiovascular and renal protection: a sodium-glucose cotransporter 2 (SGLT2) inhibitor (empagliflozin), an angiotensin II receptor blocker (losartan), and a non-steroidal mineralocorticoid receptor antagonist (finerenone). The combination is specifically targeted at patients with Type 2 Diabetes Mellitus who are at high risk for heart failure, as determined by WATCH-DM risk scores. By consolidating these medications into a single daily polycapsule, the strategy aims to improve medication adherence and clinical outcomes, such as peak oxygen uptake (VO2), compared to the standard care of prescribing the individual components separately.
- Other names
- PolyPreventHF polypillUTSW diabetic cardiomyopathy polypillempagliflozin/losartan/finerenone polypill
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)SGLT2 (Sodium-glucose cotransporter protein subunit 2)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on empagliflozin + losartan + finerenone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on empagliflozin + losartan + finerenone.